INR 117.16
(-0.66%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | 691.19 Million INR | -41.15% |
2022 | 1.19 Billion INR | -12.2% |
2021 | 1.36 Billion INR | 9.74% |
2020 | 1.24 Billion INR | 48.1% |
2019 | 837.82 Million INR | 21.91% |
2018 | 687.22 Million INR | -37.7% |
2017 | 1.1 Billion INR | 36.51% |
2016 | 808.06 Million INR | 21.79% |
2015 | 663.47 Million INR | 62.47% |
2014 | 408.35 Million INR | 55.05% |
2013 | 263.36 Million INR | 107.52% |
2012 | 126.91 Million INR | -58.27% |
2011 | 304.09 Million INR | 65.78% |
2010 | 183.43 Million INR | 21.76% |
2009 | 150.65 Million INR | 16.1% |
2008 | 129.76 Million INR | 32.02% |
2007 | 98.29 Million INR | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q1 | 226.8 Million INR | 26.29% |
2023 Q2 | 306.48 Million INR | 45.03% |
2023 Q1 | 211.31 Million INR | -8.57% |
2023 FY | 703.6 Million INR | -41.15% |
2023 Q4 | 286.07 Million INR | 2.97% |
2023 Q3 | 277.8 Million INR | -9.36% |
2022 Q3 | 299.59 Million INR | -8.42% |
2022 Q4 | 231.12 Million INR | -22.85% |
2022 FY | 1.19 Billion INR | -12.2% |
2022 Q1 | 337.64 Million INR | -26.6% |
2022 Q2 | 327.14 Million INR | -3.11% |
2021 Q3 | 268.69 Million INR | -20.81% |
2021 Q2 | 339.3 Million INR | 15.03% |
2021 Q1 | 294.96 Million INR | 17.85% |
2021 Q4 | 460 Million INR | 71.2% |
2021 FY | 1.36 Billion INR | 9.74% |
2020 Q2 | 360.85 Million INR | 17.88% |
2020 FY | 1.24 Billion INR | 48.1% |
2020 Q1 | 306.11 Million INR | 44.16% |
2020 Q4 | 250.29 Million INR | -22.65% |
2020 Q3 | 323.6 Million INR | -10.32% |
2019 Q4 | 212.33 Million INR | 4.01% |
2019 FY | 837.82 Million INR | 21.91% |
2019 Q1 | 210.92 Million INR | 201.65% |
2019 Q2 | 210.4 Million INR | -0.24% |
2019 Q3 | 204.16 Million INR | -2.97% |
2018 Q1 | 210.5 Million INR | -20.75% |
2018 FY | 687.22 Million INR | -37.7% |
2018 Q4 | 69.92 Million INR | -58.65% |
2018 Q3 | 169.1 Million INR | -28.86% |
2018 Q2 | 237.69 Million INR | 12.92% |
2017 Q2 | 319.23 Million INR | 8.29% |
2017 FY | 1.1 Billion INR | 36.51% |
2017 Q4 | 265.62 Million INR | -5.31% |
2017 Q1 | 294.8 Million INR | 0.01% |
2017 Q3 | 280.51 Million INR | -12.13% |
2016 Q2 | 246.6 Million INR | 8.82% |
2016 FY | 808.06 Million INR | 21.79% |
2016 Q4 | 294.77 Million INR | 1.88% |
2016 Q3 | 289.34 Million INR | 17.33% |
2016 Q1 | 226.62 Million INR | 605.7% |
2015 FY | 663.47 Million INR | 62.47% |
2015 Q1 | 182.76 Million INR | 7880.83% |
2015 Q2 | 240.15 Million INR | 31.4% |
2015 Q3 | 208.45 Million INR | -13.2% |
2015 Q4 | 32.11 Million INR | -84.59% |
2014 Q3 | 148.3 Million INR | 11.05% |
2014 Q4 | 2.29 Million INR | -98.46% |
2014 Q2 | 133.54 Million INR | 7.5% |
2014 Q1 | 124.22 Million INR | 478.33% |
2014 FY | 408.35 Million INR | 55.05% |
2013 Q1 | 43.39 Million INR | 175.37% |
2013 FY | 263.36 Million INR | 107.52% |
2013 Q4 | -32.83 Million INR | -123.67% |
2013 Q3 | 138.73 Million INR | 21.64% |
2013 Q2 | 114.05 Million INR | 162.86% |
2012 Q3 | 91.71 Million INR | 58.21% |
2012 Q2 | 57.97 Million INR | 66.59% |
2012 Q1 | 34.79 Million INR | 140.95% |
2012 FY | 126.91 Million INR | -58.27% |
2012 Q4 | -57.57 Million INR | -162.77% |
2011 FY | 304.09 Million INR | 65.78% |
2011 Q3 | 117.58 Million INR | 0.0% |
2011 Q4 | -84.97 Million INR | -172.26% |
2010 FY | 183.43 Million INR | 21.76% |
2009 FY | 150.65 Million INR | 16.1% |
2008 FY | 129.76 Million INR | 32.02% |
2007 FY | 98.29 Million INR | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
Sigachi Industries Limited | 2 Billion INR | 65.48% |
Ind-Swift Limited | 2.17 Billion INR | 68.185% |
Bajaj HealthCare Limited | 1.47 Billion INR | 53.038% |
Sakar Healthcare Limited | 699.58 Million INR | 1.2% |
Aurobindo Pharma Limited | 109.54 Billion INR | 99.369% |
Innova Captab Limited | 3.46 Billion INR | 80.049% |
Divi's Laboratories Limited | 32.44 Billion INR | 97.869% |
AstraZeneca Pharma India Limited | 6.22 Billion INR | 88.892% |
Morepen Laboratories Limited | 6.16 Billion INR | 88.782% |
Mankind Pharma Limited | 42.19 Billion INR | 98.362% |
Sequent Scientific Limited | 2.97 Billion INR | 76.796% |
Wanbury Limited | 1.73 Billion INR | 60.061% |
Laurus Labs Limited | 15.44 Billion INR | 95.526% |
Nectar Lifesciences Limited | 4.82 Billion INR | 85.67% |
Glenmark Life Sciences Limited | 12.43 Billion INR | 94.441% |
Alembic Limited | 1 Billion INR | 30.888% |
Hikal Limited | 5.95 Billion INR | 88.399% |
Alembic Pharmaceuticals Limited | 26.78 Billion INR | 97.419% |
Neuland Laboratories Limited | 8.24 Billion INR | 91.62% |
J. B. Chemicals & Pharmaceuticals Limited | 15.25 Billion INR | 95.47% |
Glenmark Pharmaceuticals Limited | 69.34 Billion INR | 99.003% |
IOL Chemicals and Pharmaceuticals Limited | 4.71 Billion INR | 85.353% |
Themis Medicare Limited | 2.42 Billion INR | 71.438% |
RPG Life Sciences Limited | 2.48 Billion INR | 72.163% |
Zydus Lifesciences Limited | 125.21 Billion INR | 99.448% |
Lupin Limited | 125.09 Billion INR | 99.447% |
Amrutanjan Health Care Limited | 2.09 Billion INR | 66.992% |
Wockhardt Limited | 7.72 Billion INR | 91.047% |
Vaishali Pharma Limited | 90.32 Million INR | -665.246% |
Aarti Pharmalabs Limited | 5.83 Billion INR | 88.147% |
Jagsonpal Pharmaceuticals Limited | 652.59 Million INR | -5.915% |
Jubilant Pharmova Limited | 19.64 Billion INR | 96.481% |
FDC Limited | 6.58 Billion INR | 89.505% |
Dr. Reddy's Laboratories Limited | 163.6 Billion INR | 99.578% |
Kilitch Drugs (India) Limited | 620.47 Million INR | -11.397% |
Eris Lifesciences Limited | 10.42 Billion INR | 93.371% |
Venus Remedies Limited | 2.18 Billion INR | 68.331% |
ZIM Laboratories Limited | 1.26 Billion INR | 45.481% |
Bliss GVS Pharma Limited | 3.69 Billion INR | 81.296% |
Par Drugs and Chemicals Limited | 529.13 Million INR | -30.627% |
Caplin Point Laboratories Limited | 9.2 Billion INR | 92.492% |
Shilpa Medicare Limited | 3.56 Billion INR | 80.595% |
Albert David Limited | 1.4 Billion INR | 50.913% |
Ajanta Pharma Limited | 21.06 Billion INR | 96.719% |
Hester Biosciences Limited | 1.27 Billion INR | 45.731% |
Suven Pharmaceuticals Limited | 4.12 Billion INR | 83.237% |
Solara Active Pharma Sciences Limited | -1.65 Billion INR | 141.741% |
Gufic Biosciences Limited | 4.07 Billion INR | 83.033% |
Windlas Biotech Limited | 1.33 Billion INR | 48.372% |
Procter & Gamble Health Limited | 5.78 Billion INR | 88.045% |
Aarey Drugs & Pharmaceuticals Limited | 113.02 Million INR | -511.518% |
Granules India Limited | 16.79 Billion INR | 95.886% |
Aarti Drugs Limited | 8.31 Billion INR | 91.689% |
Bal Pharma Limited | 770.19 Million INR | 10.257% |
Alkem Laboratories Limited | 52.29 Billion INR | 98.678% |
Sun Pharmaceutical Industries Limited | 258.48 Billion INR | 99.733% |
Lincoln Pharmaceuticals Limited | 1.88 Billion INR | 63.368% |
Medicamen Biotech Limited | 495.49 Million INR | -39.495% |
Unichem Laboratories Limited | 4.86 Billion INR | 85.792% |
Bafna Pharmaceuticals Limited | 452.15 Million INR | -52.867% |
Biofil Chemicals and Pharmaceuticals Limited | 12.54 Million INR | -5409.709% |
Valiant Laboratories Limited | 138.02 Million INR | -400.759% |
Orchid Pharma Limited | 2.32 Billion INR | 70.211% |
Medico Remedies Limited | 262.14 Million INR | -163.669% |
Ind-Swift Laboratories Limited | 4.13 Billion INR | 83.277% |
Ipca Laboratories Limited | 48.58 Billion INR | 98.577% |
Brooks Laboratories Limited | 65.62 Million INR | -953.327% |
Syncom Formulations (India) Limited | 559.5 Million INR | -23.537% |
Piramal Enterprises Limited | 8.04 Billion INR | 91.407% |
Torrent Pharmaceuticals Limited | 46.75 Billion INR | 98.522% |
NATCO Pharma Limited | 25.73 Billion INR | 97.314% |
Suven Life Sciences Limited | -200.79 Million INR | 444.225% |
Krebs Biochemicals & Industries Limited | -108.74 Million INR | 735.597% |
Strides Pharma Science Limited | 14.38 Billion INR | 95.196% |
Indoco Remedies Limited | 8.04 Billion INR | 91.406% |
Alpa Laboratories Limited | 188.89 Million INR | -265.914% |
Lasa Supergenerics Limited | 121.02 Million INR | -471.092% |
Sun Pharma Advanced Research Company Limited | 391.06 Million INR | -76.746% |